A Review Of ITD-1
Kantarjian et al53 assessed the efficacy and safety of dasatinib, as compared with imatinib, for the 1st-line therapy of CML-CP. 5 hundred and nineteen patients with freshly diagnosed CML-CP were randomly assigned to obtain dasatinib in a dose of 100 mg at the time every day (259 patients) or imatinib in a dose of 400 mg the moment everyday (260 cl